Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Список исп. литературыСкрыть список 1. Omori IM et al. Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J Psychopharmacol 2009; 23 (5): 539–50. 2. Gaynes BN et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med 2008; 75: 57–66. 3. Warden D et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiat Rep 2007; 9: 449–59. 4. Морозов П.В. Энигма s-рецепторов. Психиатр. и психофармакотер. 2009; 11 (2): 58–60. 5. Романов Д.В. s1-Рецепторы как потенциальная мишень психофармакотерапии. Психиатр. и психофармакотер. 2011; 13 (6): 56–60. 6. Иванов С.В. Эффекты флувоксамина и других антидепрессантов на метаболизм мелатонина. Психиатр. и психофармакотер. 2008; 5 (10): 28–30. 7. Härtter S et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21 (2): 167–74. 8. Christensen M et al. Low daily 10 mg and 20 mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P-4501A2) and omeprazole (cytochrome P-4502C19). Clin Pharmacol Ther 2002; 71 (3): 141–52. 9. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997; 62 (3): 279–86. 10. Jeppesen U et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51 (1): 73–8. 11. Sunami E et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med 2012; 51 (10): 1187–93. 12. Grözinger M et al. Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile. Arch Gen Psychiat 2000; 57 (8): 812–3. 13. Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Met Dis 2010; 38: 1381–91. 14. Hermesh H et al. Circadian rhythm sleep disorders as a possible side effect of fluvoxamine. CNS Spectr 2001; 6 (6): 511–3. 15. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9 (1): 25–39. 16. Duncan WC. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996; 71 (3): 253–312. 17. Quera Salva MA et al. Circadian rhythms, melatonin and depression. Curr Pharm Des 2011; 17 (15): 1459–70. 18. Childs PA et al. Effect of fluoxetine on melatonin in patients with seasonal affective disorder and matched controls. Br J Psychiat 1995; 166 (2): 196–8. 19. Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiat Scand Suppl 2013; 128: 16–23. 20. Touitou Y, Bogdan A. Promoting adjustment of the sleep-wake cycle by chronobiotics. Physiol Behav 2007; 90 (2–3): 294–300. 21. Srinivasan V et al. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. Travel Med Infect Dis 2008; 6 (1–2): 17–28. 22. Srinivasan V et al. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther 2010; 27 (11): 796–813. 23. Souêtre E et al. Circadian rhythms in depression and recovery: Evidence for blunted amplitude as the main chronobiological abnormality. Psychiat Res 1989; 28 (3): 263–78. 24. Srinivasan V et al. Melatonin in mood disorders. World J Biol Psychiat Infor UK Ltd UK 2006; 7 (3): 138–51. 25. Etain B et al. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum Mol Gen 2012; 21 (18): 4030–7. 26. Serfaty MA et al. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010; 25: 132–42. 27. Buckley TM, Schatzberg AF. A pilot study of the phase angle between cortisol and melatonin in major depression – a potential biomarker? J Psychiat Res 2010; 44 (2): 69–74. 28. Wetterberg L. Melatonin in humans physiological and clinical studies. J Neural Transm Suppl 1978; pp. 289–310. 29. McIntyre IM et al. Plasma melatonin levels in affective states. Int J Clin Pharmacol Res 1989; 9: 159–64. 30. Frazer A et al. Patterns of melatonin rhythms in depression. J Neural Transm Suppl 1986; 21: 269–90. 31. Parry BL et al. Sleep, rhythms and women’s mood. Part II. Menopause Sleep Med Rev 2006; 10: 197–208. 32. Checkley S. The relationship between biological rhythms and the affective disorders. In: J.Arendt, D.Minors, J.Waterhouse (ed.). Biological rhythms in clinical practice. London: Wright 1989; pp. 160–83. 33. Sekula LK et al. Neuroendocrine aspects of primary endogenous depression XV: Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiat Res 1997; 69: 143–53. 34. Crasson M et al. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinol 2004; 29 (1): 1–12. 35. Fountoulakis KN et al. Morning and evening plasma melatonin and dexamethasone suppression test in patients with nonseasonal major depressive disorder from northern Greece (latitude 40–41,5 degrees). Neuropsychobiol 2001; 44 (3): 113–7. 36. Brown RP et al. Depressed mood and reality disturbance correlate with decreased nocturnal melatonin in depressed patients. Acta Psychiat Scand 1987; 76 (3): 272–5. 37. Srinivasan V et al. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiat 2011; 35 (4): 913–23. 38. Carman JS et al. Negative effects of melatonin on depression. Am J Psychiat 1976; 133: 1181–6. 39. Rahman SA, Kayumov L, Shapiro CM. Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome. Sleep Med 2010; 11 (2): 131–6. 40. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 2006; 21 (Suppl. 1): s11–5. 41. Buscemi N et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20 (12): 1151–8. 42. Wilhelmsen-Langeland A et al. A randomized controlled trial with bright light and melatonin for the treatment of delayed sleep phase disorder: effects on subjective and objective sleepiness and cognitive function. J Biol Rhythms 2013; 28 (5): 306–21. 43. Nagtegaal JE et al. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res 2000; 48 (1): 45–50. 44. Fiorentino L, Martin JL. Awake at 4 AM: treatment of insomnia with early morning awakenings among older adults. J Clin Psychol 2010; 66 (11): 1161–74. 45. Pandi-Perumal SR et al. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol Nature Publishing Group 2008; 4 (8): 436–47. 46. Mendlewicz J. Efficacy of fluvoxamine in severe depression. Drugs 1992; 43 (Suppl. 2): 32–7. disc. 37–9. 47. Zohar J, Keegstra H, Barrelet L. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol 2003; 18 (2): 113–9. 48. Ottevanger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuropsychopharmacol Biol Psychiat 1994; 18 (4): 731–40. 49. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spect 2005; 10 (4): 319–23. 50. Furuse T, Hashimoto K. Fluvoxamine monotherapy for psychotic depression: the potential role of s1-receptors. Ann Gen Psychiat 2009; 8: 26. 51. Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiat 2002; 35: 101–8. 52. Wagner W, Zaborny BA, Gray TE. Fluvoxamine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994; 9 (4): 223–7. 53. Незнамов Г.Г., Сюняков С.А., Телешова Е.С. и др. Терапевтическое действие и эффективность феварина (флувоксамина) у больных с непсихотическими тревожными и апато-адинамическими депрессиями. Журн. неврол. и психиатр. им. С.С.Корсакова. 2001; 101. 54. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P-450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29 (3): 192–209. 55. Kupfer DJ et al. Fluvoxamine versus desipramine: Comparative polysomnographic effects. Biol Psychiat 1991; 29: 23–40. 56. Westenberg HGM, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006; 60 (4): 482–91.